⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VKTX News
Viking Therapeutics, Inc
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors
prnewswire.com
VKTX
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
prnewswire.com
VKTX
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
prnewswire.com
ELDN
VRTX
VKTX
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
globenewswire.com
VKTX
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
prnewswire.com
ABCL
VKTX
HYFT
ABSI
NVDA
Oral Obesity Therapies Market to Reach $6.32 Billion by 2030 as Demand for GLP-1 Treatments Accelerates
globenewswire.com
MRK
PFE
AZN
LLY
VKTX
STRT
Complicated Urinary Tract Infections Market Report, Analyzes Treatment Needs Across Elderly, Diabetic, and Immunosuppressed Populations
globenewswire.com
ABBV
PFE
GALT
VKTX
LPCN
ALGS
LLY
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
prnewswire.com
VKTX
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
prnewswire.com
VKTX